Literature DB >> 990155

A study of labetalol in patients of European, West Indian and West African origin.

K Jennings, V Parsons.   

Abstract

1 Hypertension in West Indians and Africans is common and has an unacceptably high mortality in the younger patients. 2 Fifty-three patients received labetalol (a combined alpha- and beta-adrenoreceptor antagonist) as part of an open evaluation of its anti-hypertensive effect. Ten non-caucasian patients were included. 3 Significant reductions in systolic and diastolic pressures were obtained in the caucasian patients, the African and West Indian patients remaining refractory to therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 990155

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  Propranolol versus labetalol: interesting differences in efficacy.

Authors:  W Flamenbaum
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

4.  Labetalol: the nineteen-eighties.

Authors:  J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 5.  Cost effectiveness of labetalol and propranolol in the treatment of hypertension among blacks.

Authors:  G Oster; D M Huse; T E Delea; D D Savage; G A Colditz
Journal:  J Natl Med Assoc       Date:  1987-10       Impact factor: 1.798

6.  Labetalol in essential hypertension.

Authors:  A Breckenridge; M Orme; M J Serlin; M Maciver
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 7.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Comparison of black and white patients attending hypertension clinics in England.

Authors:  A D Munro-Faure; L J Beilin; C J Bulpitt; E C Coles; C T Dollery; J S Gear; G Harper; B F Johnson
Journal:  Br Med J       Date:  1979-04-21

9.  Labetalol-induced toxic myopathy.

Authors:  A Teicher; T Rosenthal; E Kissin; I Sarova
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-06

10.  Altered beta-2 adrenergic receptor gene expression in human clinical hypertension.

Authors:  Jennifer R Dungan; Yvette P Conley; Taimour Y Langaee; Julie A Johnson; Shawn M Kneipp; Philip J Hess; Carolyn B Yucha
Journal:  Biol Res Nurs       Date:  2009-03-01       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.